Publicaciones en colaboración con investigadores/as de University of Lorraine (10)

2024

  1. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 7, pp. 1891-1908

  2. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart

2023

  1. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial

    JHEP Reports, Vol. 5, Núm. 5

  2. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

2020

  1. A Role for MMP-10 (Matrix Metalloproteinase-10) in Calcific Aortic Valve Stenosis

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 40, Núm. 5, pp. 1370-1382

  2. Postoperative Radiation Therapy in Patients with Extracranial Chondrosarcoma: A Joint Study of the French Sarcoma Group and Rare Cancer Network

    International Journal of Radiation Oncology Biology Physics

2019

  1. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation: Mechanistic insights and clinical implications

    Hypertension, Vol. 73, Núm. 3, pp. 602-611

  2. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

    Heart, Vol. 105, Núm. 4, pp. 307-314

2018

  1. Role of amino-acid PET in high-grade gliomas: Limitations and perspectives

    Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 62, Núm. 3, pp. 254-266